DE3774279D1 - Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe. - Google Patents

Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe.

Info

Publication number
DE3774279D1
DE3774279D1 DE8787907789T DE3774279T DE3774279D1 DE 3774279 D1 DE3774279 D1 DE 3774279D1 DE 8787907789 T DE8787907789 T DE 8787907789T DE 3774279 T DE3774279 T DE 3774279T DE 3774279 D1 DE3774279 D1 DE 3774279D1
Authority
DE
Germany
Prior art keywords
pharmaceutically active
pct
body tissue
specificity
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787907789T
Other languages
English (en)
Inventor
Albert Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central Blood Laboratories Authority
Original Assignee
Central Blood Laboratories Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central Blood Laboratories Authority filed Critical Central Blood Laboratories Authority
Application granted granted Critical
Publication of DE3774279D1 publication Critical patent/DE3774279D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • C12N9/6462Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153Streptokinase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21073Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8787907789T 1986-11-27 1987-11-27 Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe. Expired - Fee Related DE3774279D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868628398A GB8628398D0 (en) 1986-11-27 1986-11-27 Pharmaceutically-active conjugates
PCT/GB1987/000854 WO1988003810A1 (en) 1986-11-27 1987-11-27 Pharmaceutically active conjugates having improved body tissue binding specificity

Publications (1)

Publication Number Publication Date
DE3774279D1 true DE3774279D1 (de) 1991-12-05

Family

ID=10608055

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787907789T Expired - Fee Related DE3774279D1 (de) 1986-11-27 1987-11-27 Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe.

Country Status (10)

Country Link
US (1) US5151412A (de)
EP (1) EP0333740B1 (de)
JP (1) JP2721830B2 (de)
AT (1) ATE68977T1 (de)
AU (1) AU610104B2 (de)
DE (1) DE3774279D1 (de)
DK (1) DK168693B1 (de)
GB (1) GB8628398D0 (de)
NO (1) NO177526C (de)
WO (1) WO1988003810A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0340573A3 (de) * 1988-04-30 1990-05-30 BASF Aktiengesellschaft Neue Proteine, ihre Herstellung und Verwendung
US4892826A (en) * 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
ATE135584T1 (de) * 1988-12-20 1996-04-15 Jolla Cancer Res Found Polypeptid-polymer-konjugate mit wundheilender wirkung
EP0429663A1 (de) * 1989-06-13 1991-06-05 Nippon Soda Co., Ltd. Der menschlichen prourokinase ähnliche polypeptide und verfahren zu deren herstellung
US5124320A (en) * 1989-09-12 1992-06-23 Ivy Jeffery W An external analgesic lotion containing active ingredients of camphor and menthol and method of making such lotion
US5013726A (en) * 1989-09-12 1991-05-07 Ivy Jeffery W External analgesic lotion containing active ingredients of methyl salicylate and camphor and menthol and method of making such lotion
GB9023149D0 (en) * 1990-10-24 1990-12-05 British Bio Technology Proteins and nucleic acids
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations
CA2114629C (en) * 1991-07-31 2003-01-14 Howard C. Krivan Receptor conjugates for targeting antibiotics to bacteria
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
CN1091315A (zh) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 血纤维蛋白封闭剂组合物及其使用方法
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
DE4242736A1 (de) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
WO1994017097A1 (en) * 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
US5821074A (en) * 1993-12-21 1998-10-13 Abbott Laboratories Method and compositions for enhancing aminolevulinic acid dehydratase assay
CA2253204A1 (en) * 1996-05-03 1997-11-13 Roger S. Cubicciotti Prodrug compositions and drug delivery methods using synthetic receptors
EP1042367A1 (de) * 1997-12-24 2000-10-11 Immunex Corporation V196 dna und polypeptide
AU756913B2 (en) * 1998-08-21 2003-01-23 Immunex Corporation Human IL-1 epsilon DNA and polypeptides
IN190822B (de) * 1998-12-24 2003-08-23 Council Scient Ind Res
US7678767B2 (en) * 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20100297218A1 (en) * 2006-09-20 2010-11-25 Pneumrx, Inc. Tissue adhesive compositions and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
JPS59134732A (ja) * 1983-01-21 1984-08-02 Green Cross Corp:The フイブロネクチン・生理活性物質複合体の製造法
JPS60226819A (ja) * 1984-04-25 1985-11-12 Green Cross Corp:The フイブロネクチン複合体
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates
US4587122A (en) * 1985-04-23 1986-05-06 The Green Cross Corporation Fibronectin-dextran-drug complex and method of preparation thereof

Also Published As

Publication number Publication date
DK420988A (da) 1988-07-27
AU610104B2 (en) 1991-05-16
EP0333740B1 (de) 1991-10-30
JP2721830B2 (ja) 1998-03-04
GB8628398D0 (en) 1986-12-31
DK420988D0 (da) 1988-07-27
DK168693B1 (da) 1994-05-24
US5151412A (en) 1992-09-29
EP0333740A1 (de) 1989-09-27
AU8277387A (en) 1988-06-16
JPH02501305A (ja) 1990-05-10
NO883306D0 (no) 1988-07-26
NO177526C (no) 1995-10-04
NO177526B (no) 1995-06-26
NO883306L (no) 1988-07-26
WO1988003810A1 (en) 1988-06-02
ATE68977T1 (de) 1991-11-15

Similar Documents

Publication Publication Date Title
DE3774279D1 (de) Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe.
ATE324119T1 (de) Verwendung von saccharid-konjugaten
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
CY1112845T1 (el) Παραγωγα της 1-δεοξυ-γαλακτονογιριμυκινης και η χρηση τους στη θεραπεια αθροιστικων λυσοσωμικων ασθενειων μεσω ενισχυσης της λυσοσωμικης α-γαλακτοσιδασης α
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
DE3877196T2 (de) Maschine fuer die behandlung von boegen.
DE68905000T2 (de) Zusammensetzung fuer die behandlung von fasern.
UY25263A1 (es) 6-derivados sustitutivos del ácido micofenólico.-
EP0786995A4 (de)
PL335140A1 (en) Therapeutic agent for treating lymphatic system carcinomas
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
DE3876140T2 (de) Zusammensetzung fuer die behandlung von textilien.
NO870397D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive organiske platinakomplekser.
DE3781652D1 (de) Zubereitung, geeignet fuer die behandlung von darmstoerungen.
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
ATE114974T1 (de) Abgabe von cytotoxischen mitteln.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
MY124071A (en) Treatment of viral disease in swine
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
ATE317021T1 (de) Antisense modulierung von lfa-3

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee